Navigation Links
Agendia Launches TargetPrint(R) for Breast Cancer Patients
Date:9/4/2008


Optimizing Patient Identification for Targeted Therapies

That Ensure Benefits of Personalized Treatment HUNTINGTON BEACH, Calif., and AMSTERDAM, Netherlands, Sept. 4 /PRNewswire/ -- Agendia, a world leader in molecular cancer diagnostics, today announced the launch of TargetPrint(R), a new diagnostic test that allows physicians to quantitatively determine the gene expression levels of the estrogen receptor (ER), progesterone receptor (PR) and Human Epidermal growth factor Receptor 2 (HER2) in breast cancer tumor biopsies. The accurate measurement of these receptors is of paramount importance in planning treatment of breast cancer patients after surgery and assists physicians and patients in making informed treatment decisions. TargetPrint runs on Agendia's new High Density Chip, which received market clearance last month (August 2008) from the U.S. Food and Drug Administration (FDA).

"Currently available targeted therapies, such as hormone treatments, can have a huge impact on the survival and quality of life of a significant number of breast cancer patients," said Bernhard Sixt, Ph.D., president and chief executive officer of Agendia. "TargetPrint will play a key role in defining which patients are most likely to benefit from these treatments."

"The test's results give a precise molecular read-out of prognostic parameters for breast cancer and provide physicians and patients with reliable guidance on the most suitable treatment for each individual patient," said Richard A. Bender, MD, FACP, chief medical officer of Agendia. "In the near future, it is our plan to add information on a wider range of drug targets to TargetPrint and clinically validate these with key customers."

Agendia will present clinical data on TargetPrint at The 2008 Breast Cancer Symposium which is co-sponsored by the American Society of Clinical Oncology (ASCO) and will be held in Washington, DC from September 5-7, 2008. TargetPrint is processed at Agendia's Clinical Laboratory Improvement Amendments (CLIA) certified and the College of American Pathology (CAP) accredited laboratory.

About Agendia

Agendia is a world leader in molecular cancer diagnostics. The company markets four products based on its breakthrough platform for tumor gene expression profiling and has several new diagnostic tests under development. Agendia was the first company to receive FDA clearance for a breast cancer test, MammaPrint(R), that predicts the risk of breast cancer recurrence. In addition, the company collaborates with pharma companies to develop highly effective personalized drugs in the area of oncology. Agendia is based in Huntington Beach, California, and in Amsterdam, The Netherlands. For more information on Agendia, please visit http://www.agendia.com.

MEDIA CONTACTS

U.S. Media Contact: EU and non-U.S. Media:

Kelly Connor Hans Herklots

Vice President Head Corporate Communications

Ogilvy Public Relations Worldwide Agendia

+1.212.880.5328 Office +31.20.462.1557 Office

+1.609.221.5785 Mobile +31.620.083.509 Mobile

Kelly.connor@ogilvypr.com hans.herklots@agendia.com


'/>"/>
SOURCE Agendia
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Aon eSolutions Launches Clinical Trials Module
2. Landmark HIV/AIDS Publication Launches at International AIDS Society Conference in Mexico City
3. Interleukin Genetics Launches Enhanced Heart Health Genetic Test Report Format
4. Impliant Launches Less-Invasive Version of Patented TOPS(TM) Spine System
5. McGraw-Hill Professional Launches Drug Effectiveness Resource on AccessPharmacy
6. Kansas Invests Millions in Innovations to Improve Human Health and Launches Three National Bioscience Programs at BIO08
7. Diplomat Specialty Pharmacy Develops and Launches Best-In-Class Electronic Navigator (eNAV(TM)) Patient Care System
8. BASF Officially Launches the Collaborative Advanced Research Initiative at Harvard University
9. The COSHAR Foundation Launches National Childhood Immunization Awareness Campaign During National Infant Immunization Week (April 19-26)
10. CardioMind Launches First-in-Human Trial of Small Vessel, Drug-Eluting Stent
11. Lilly Launches Its First Phase III Trial for Treatment of Alzheimers Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) announced ... Act of 1976, as amended ("HSR"), with respect to ... CPXX ) expired effective June 24, 2016, ... previously announced on May 31, 2016, Jazz Pharmaceuticals and ... Jazz Pharmaceuticals has commenced a tender offer for all ...
(Date:6/26/2016)... 2016 Story Highlights: ... within the health care industry is causing providers to ... , Deloitte offers a suite of solutions for health ... efficient cost optimization: labor resource analysis, revenue cycle optimization ... better outcomes and better economics ...
(Date:6/24/2016)... , June 24, 2016  Collagen Matrix, ... design, development and manufacturing of collagen and mineral ... announced today that Bill Messer has ... Marketing to further leverage the growing portfolio of ... devices. Bill joins the Collagen Matrix ...
Breaking Medicine Technology:
(Date:6/26/2016)... (PRWEB) , ... June 27, 2016 , ... Quality metrics ... yet in many ways they remain in the eye of the beholder, according to ... a publication of The American Journal of Managed Care. For the full issue, ...
(Date:6/26/2016)... Clarkston, Michigan (PRWEB) , ... June 26, 2016 ... ... respect to fertility once they have been diagnosed with endometriosis. These women need ... but they also require a comprehensive approach that can help for preservation of ...
(Date:6/25/2016)... ... , ... First Choice Emergency Room , the largest network of independent ... Director of its new Mesquite-Samuell Farm facility. , “We are pleased to announce ... Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , ...
(Date:6/24/2016)... ... ... A recent article published June 14 on E Online details ... to state that individuals are now more comfortable seeking to undergo not only the ... and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) notes ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced ... attorneys chosen by their peers for this recognition are considered among the top 2 ... received special honors as members of this year’s Legal Elite Hall of Fame: ...
Breaking Medicine News(10 mins):